Longitudinal Follow-Up of a Prospective Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma Reveals Distinct Patterns of Survivorship
HPB - United Kingdom
doi 10.1016/j.hpb.2019.03.095
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
Elsevier BV